Clinical Trials Logo

Filter by:
NCT ID: NCT01414257 Completed - Arthritis Clinical Trials

Methotrexate (Rheumatrex) High Dose Special Investigation (Regulatory Post Marketing Commitment Plan)

Start date: May 2011
Phase:
Study type: Observational

This Investigation is to be performed for the purpose of assessing the following information in the long-term post-marketing daily medical practice in the patients who receive REUMATOLEX 2 mg Capsule for the treatment of Rheumatoid Arthritis (RA) at the dose higher than 8 mg/week. 1. Condition of occurrence of ADRs 2. Factors considered to affect safety 3. Verification of efficacy

NCT ID: NCT01414140 Completed - Contraception Clinical Trials

Mirena Post-marketing Surveillance in Japan

Start date: May 2007
Phase: N/A
Study type: Observational

This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of women who are inserted Mirena for intrauterine contraception. The objective of this study is to assess safety and effectiveness of Mirena under real-life practice conditions. A total 550 patients will be recruited and followed for 5 years.

NCT ID: NCT01413906 Completed - Cancer Clinical Trials

Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors

Start date: November 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the tolerability and safety profile of BMS-833923 (XL139) when orally administered on a once daily schedule.

NCT ID: NCT01413204 Completed - Clinical trials for Type 2 Diabetes Mellitus

Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes

Start date: July 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of TA-7284 as monotherapy in patients with type 2 Diabetes for 24 weeks administration.

NCT ID: NCT01412944 Completed - Clinical trials for Plaque-type Psoriasis

Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis

STATURE
Start date: December 2011
Phase: Phase 3
Study type: Interventional

The study will assess the safety and efficacy of intravenous (10mg/kg) and subcutaneous (300mg) secukinumab in moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab.

NCT ID: NCT01412736 Completed - Clinical trials for Uncontrolled and Suspected Eosinophilic Asthma

A Phase IIa Study of KHK4563

4563-003
Start date: August 2011
Phase: Phase 2
Study type: Interventional

This is a double-blind, placebo-controlled dose-ranging study of KHK4563 to evaluate the effect of multiple-dose subcutaneous administration of KHK4563 on the annual asthma exacerbation rate in adult subjects with uncontrolled, suspected eosinophilic asthma.

NCT ID: NCT01412671 Completed - Clinical trials for Carcinoma, Renal Cell

Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program

Start date: February 27, 2008
Phase:
Study type: Observational

This study is an early access program of 'Nexavar post-marketing surveillance (PMS) for renal cell carcinoma (RCC) in Japan' which is a regulatory, local prospective and observational study for patients with unresectable or advanced RCC under real-life practice conditions. The objective of this study is to assess safety and effectiveness of Nexavar at some limited sites which joined to clinical trial of Nexavar, before available of it in the market. The enrollment period is 2 months, and patients who received Nexavar will be recruited and followed one year since starting Nexavar administration. The data of this study will be integrated into the Nexavar PMS and the data will not be analyzed and reported alone.

NCT ID: NCT01412398 Completed - Hyperphosphatemia Clinical Trials

Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan

FOSRENOL-CAPD
Start date: April 7, 2009
Phase: N/A
Study type: Observational

This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients in continuous ambulatory peritoneal dialysis (CAPD) who have received Fosrenol for hyperphosphatemia. The objective of this study is to assess safety and efficacy of using Fosrenol in clinical practice. This study is also all case investigation of which the enrollment period is one year, and all patients in CAPD who received Fosrenol for hyperphosphatemia will be recruited and followed one year.

NCT ID: NCT01412294 Active, not recruiting - Gastric Cancer Clinical Trials

XParTS: Capecitabine/Cisplatin(XP) for Recurrent Gastric Cancer

Start date: July 2011
Phase: Phase 2
Study type: Interventional

The aim of this study is to evaluate efficacy and safety of Capecitabine/Cisplatin for gastric cancer patients who relapsed after adjuvant chemotherapy by S-1.

NCT ID: NCT01411449 Completed - Diagnostic Imaging Clinical Trials

Primovist Post-marketing Surveillance in Japan

PRIMOVIST
Start date: March 11, 2008
Phase: N/A
Study type: Observational

This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Primovist for contrast enhancement in MRI of liver. The objective of this study is to assess safety, especially in relation to renal dysfunction, and efficacy of using Primovist in clinical practice. A total 2,000 patients for diagnosis on detection and identify hepatic tumor will be recruited and followed 7 days after the injection.